Clinical trials on the efficacy of drugs in HER2-positive breast cancer with brain metastases have only recently been conducted and primarily demonstrate the benefit of tyrosine kinase inhibitors and novel drug conjugates (Müller et al., 2025). The gene discussed is ERBB2; the disease is breast carcinoma.